Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Go back to Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.| Merck & Co. (NYSE: MRK) | Delayed: 145.14 +0.43 (0.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.71 | 52 Week High | $65.46 | |||
| Open | $145.52 | 52 Week Low | $47.97 | |||
| Day High | $145.90 | P/E | 98.73 | |||
| Day Low | $143.82 | EPS | $1.47 | |||
| Volume | 2,519,324 | |||||
| IGNYTA (NASDAQ: RXDX) | Delayed: 199.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.92 | 52 Week High | $15.20 | |||
| Open | $10.02 | 52 Week Low | $4.15 | |||
| Day High | $199.92 | P/E | N/A | |||
| Day Low | $199.92 | EPS | $-0.44 | |||
| Volume | 417,305 | |||||
